Richard M. Myers
Founder at SwitchGear Genomics, Inc.
Profile
Richard M.
Myers is the founder of SwitchGear Genomics, Inc. (founded in 2006) and holds the title of Chairman-Scientific Advisory.
Dr. Myers is also the founder of Imidomics, Inc. Dr. Myers's current job is Chief Scientific Officer at The HudsonAlpha Institute for Biotechnology.
Dr. Myers's former job was Chairman-Genetics Department at Stanford University.
Richard M. Myers active positions
Companies | Position | Start |
---|---|---|
SwitchGear Genomics, Inc.
SwitchGear Genomics, Inc. BiotechnologyHealth Technology SwitchGear Genomics, Inc. provides products for studying regulatory elements in the human genome. It launches LightSwitch Synthetic Response Element which is used for understanding transcription factor activity in living cells. The firms endogenous human promoter vectors are used in primary screening assays to understand how drug candidates may affect biological pathways. The company was founded by Richard M. Myers, Nathan D. Trinklein and Shelley Force Aldred in 2006 and is headquartered in Menlo Park, CA. | Founder | 2005-12-31 |
The HudsonAlpha Institute for Biotechnology
The HudsonAlpha Institute for Biotechnology BiotechnologyHealth Technology The HudsonAlpha Institute for Biotechnology is a non-profit organization. It focuses on conducting genomics-based research to improve human health and well being; implementing genomic medicine, sparking economic development; and providing educational outreach to nurture the next generation of biotech researchers and entrepreneurs, as well as to create a biotech literate public. The company was founded by James R. Hudson, Jr. and Lonnie S. McMillian in 2008 and is headquartered in Huntsville, AL. | Chief Tech/Sci/R&D Officer | 2022-06-30 |
Imidomics, Inc.
Imidomics, Inc. BiotechnologyHealth Technology Imidomics, Inc. is an American biotechnology company that focuses on discovering and developing new medicines for immune-mediated inflammatory diseases (IMIDs). The company is based in an undisclosed location. Imidomics has access to the IMID-biobank, which includes real-world data from clinical records and biological samples from over 17,000 IMID patients and control subjects across six indications. The company utilizes a proprietary digital bioinformatics portal called the Imidomics Precision Discovery Platform to generate novel insights into disease mechanisms and identify potential new drug targets. The company was founded in Barcelona in 2015 by Dr. Sara Marsal and Dr. Richard M. Myers. The CEO of the company is Fred Bernard Craves. | Founder | - |
Former positions of Richard M. Myers
Companies | Position | End |
---|---|---|
Stanford University | Corporate Officer/Principal | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 3 |
---|---|
SwitchGear Genomics, Inc.
SwitchGear Genomics, Inc. BiotechnologyHealth Technology SwitchGear Genomics, Inc. provides products for studying regulatory elements in the human genome. It launches LightSwitch Synthetic Response Element which is used for understanding transcription factor activity in living cells. The firms endogenous human promoter vectors are used in primary screening assays to understand how drug candidates may affect biological pathways. The company was founded by Richard M. Myers, Nathan D. Trinklein and Shelley Force Aldred in 2006 and is headquartered in Menlo Park, CA. | Health Technology |
The HudsonAlpha Institute for Biotechnology
The HudsonAlpha Institute for Biotechnology BiotechnologyHealth Technology The HudsonAlpha Institute for Biotechnology is a non-profit organization. It focuses on conducting genomics-based research to improve human health and well being; implementing genomic medicine, sparking economic development; and providing educational outreach to nurture the next generation of biotech researchers and entrepreneurs, as well as to create a biotech literate public. The company was founded by James R. Hudson, Jr. and Lonnie S. McMillian in 2008 and is headquartered in Huntsville, AL. | Health Technology |
Imidomics, Inc.
Imidomics, Inc. BiotechnologyHealth Technology Imidomics, Inc. is an American biotechnology company that focuses on discovering and developing new medicines for immune-mediated inflammatory diseases (IMIDs). The company is based in an undisclosed location. Imidomics has access to the IMID-biobank, which includes real-world data from clinical records and biological samples from over 17,000 IMID patients and control subjects across six indications. The company utilizes a proprietary digital bioinformatics portal called the Imidomics Precision Discovery Platform to generate novel insights into disease mechanisms and identify potential new drug targets. The company was founded in Barcelona in 2015 by Dr. Sara Marsal and Dr. Richard M. Myers. The CEO of the company is Fred Bernard Craves. | Health Technology |
- Stock Market
- Insiders
- Richard M. Myers